Concourse Financial Group Securities, Inc. Kazia Therapeutics LTD Transaction History
Concourse Financial Group Securities, Inc.
- $1.56 Billion
- Q2 2024
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding KZIA
# of Institutions
13Shares Held
328KCall Options Held
24KPut Options Held
0-
Morgan Stanley New York, NY201KShares$68,3670.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA41.5KShares$14,1020.0% of portfolio
-
Virtu Financial LLC New York, NY39.3KShares$13,3540.0% of portfolio
-
Ubs Group Ag23.3KShares$7,9340.0% of portfolio
-
Rhumbline Advisers Boston, MA17.6KShares$5,9890.0% of portfolio
About KAZIA THERAPEUTICS LTD
- Ticker KZIA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,111,300
- Market Cap $5.14M
- Description
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...